Effects of High Altitude on AMPK Activation
| Status: | Recruiting |
|---|---|
| Conditions: | Women's Studies, Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 12/23/2018 |
| Start Date: | January 2016 |
| End Date: | June 2019 |
| Contact: | Lorna Moore, PhD |
| Email: | lorna.moore@ucdenver.edu |
| Phone: | 303-724-7474 |
Effects of High Altitude on 5' Adenosine Monophosphate-activated Protein Kinase (AMPK) Activation and Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Regulation
Pregnancy elicits adaptive changes in uteroplacental blood flow, which are altered at high
altitude and may contribute to the observed 3-fold increase in intrauterine growth
restriction (IUGR) and preeclampsia (PreE). The investigators propose to collect myometrial,
cord blood, and placental tissue samples from women at high altitude (Summit County) and low
altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy
changes the vasoreactivity of myometrial arteries (MA). If altered MA vasoreactivity is
found, further studies may be able to link these changes to the increased rates of PreE and
IUGR at altitude and contribute to the understanding of these two disorders.
altitude and may contribute to the observed 3-fold increase in intrauterine growth
restriction (IUGR) and preeclampsia (PreE). The investigators propose to collect myometrial,
cord blood, and placental tissue samples from women at high altitude (Summit County) and low
altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy
changes the vasoreactivity of myometrial arteries (MA). If altered MA vasoreactivity is
found, further studies may be able to link these changes to the increased rates of PreE and
IUGR at altitude and contribute to the understanding of these two disorders.
The Investigators will determine if residence at altitude during pregnancy changes the
vasoreactivity of myometrial arteries. This will be novel information regarding pregnancy at
altitude and of significance not just for women and families in Colorado, but also at
high-altitude locations throughout the world. If altered MA vasoreactivity is found, further
studies may be able to link these changes to the increased rates of PreE and IUGR at altitude
and contribute to the understanding of these two disorders.
The Investigators will also determine whether the chronic hypoxia of high altitude alters DNA
methylation patterns and expression of key genes involved in metabolic homeostasis in
maternal, placental and fetal cells and, in turn, the relationship of these changes to fetal
growth and maternal well-being.
vasoreactivity of myometrial arteries. This will be novel information regarding pregnancy at
altitude and of significance not just for women and families in Colorado, but also at
high-altitude locations throughout the world. If altered MA vasoreactivity is found, further
studies may be able to link these changes to the increased rates of PreE and IUGR at altitude
and contribute to the understanding of these two disorders.
The Investigators will also determine whether the chronic hypoxia of high altitude alters DNA
methylation patterns and expression of key genes involved in metabolic homeostasis in
maternal, placental and fetal cells and, in turn, the relationship of these changes to fetal
growth and maternal well-being.
Inclusion Criteria:
- Women scheduled for cesarean delivery at University of Colorado Hospital (Denver, 1600
m) and St. Anthony's Summit Medical Center (Summit County, 3000 m)
- Cesarean delivery at a prescheduled time without any labor, typically at 39 weeks
gestation
Exclusion Criteria:
- Women will be excluded if there are co-existing medical diagnoses that are known to
affect vascular parameters (i.e., diabetes mellitus, gestational diabetes, any
hypertensive disorder of pregnancy, or a current smoker).
- Women with multiple gestations and preterm deliveries will also be excluded.
We found this trial at
1
site
Aurora, Colorado 80045
Principal Investigator: Lorna Moore, PhD
Phone: 303-724-6501
Click here to add this to my saved trials
